Wynzora generic
Wynzora is a topical medication owned by Mc2. The active ingredients in Wynzora are Betamethasone Dipropionate and Calcipotriene. It was first authorized for market use on July 20, 2020.
When will Wynzora generic be available?
Wynzora holds a total of 3 patents. While none of them have expired yet, the last patent is set to expire on March 18, 2039, after which generic versions of the drug could become available. The patent holding up the release of Wynzora generic is US11696919 titled 'Topical composition'.
Wynzora uses
Wynzora is primarily used for the treatment of psoriasis. The two active ingredients, Betamethasone Dipropionate and Calcipotriene, work synergistically to reduce the inflammation and scaling associated with psoriasis.
Wynzora patent expiration
Wynzora has three patents, with the latest expiring on March 18, 2039. This is the generic release date for Wynzora's patents. The last key patent holding the generic release is US11696919 with a title 'Topical composition'. Below are the details of the patent: